Technology of DTPA and immunoglobulins conjugation and their attachment to 90Y and 177Lu radionuclides

Abstract

The aim of the study of labeling of ligand–antibody conjugates was to find optimal conditions of preparing of these conjugates and appropriate radioactivity of selected nuclide for applications in nuclear medicine. Conjugation of the γ-immunoglobulin G (human or bovine IgG, polyclonal antibodies) and bifunctional chelating agent, diethylenetriaminepentaacetic acid dianhydride (cDTPAA), was carried out. Various values of the cDTPAA/antibody ratio, the weight concentration of polyclonal or monoclonal antibodies (MEM-97) and buffers were used. Further, the labeling conditions of the DTPA–IgG conjugate by radionuclides 90Y and 177Lu were optimized, and the labeling yield and the conjugation ratio of prepared radionuclide–DTPA–IgG conjugates was determined. Optimal incubation time of the immunoglobulin conjugation was obtained at 30 min from mixing of individual components. The labeling yield of radionuclide–DTPA–antibody conjugate higher than 95% was achieved. Higher values of conjugation ratio of radionuclide–DTPA–antibody conjugate were achieved in 0.1 mol L−1 carbonate buffer, pH 8.5, and the 0.1 mol L−1 carbonate buffer is suitable for studied conjugation systems. This study showed that the labeling yield as well as the conjugation ratio of tested systems depend on the amount of antibody substance, bifunctional chelating agent/antibody molar ratio and pH value of the buffer used.